Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Metastatic Pancreatic Cancer
Interventions: Gemcitabine, Nab-paclitaxel, YL-13027; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Achondroplasia
Interventions: Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, RO5095932; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus
Interventions: My HealtheVet Brochure, My HealtheVet Training Guide for Veterans Living with Diabetes, My HealtheVet Group Training, My HealtheVet Individual Training; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Bedford, Massachusetts • Boston, Massachusetts

Conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions: Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI); Other · Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes, Cardiomyopathy
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sex Chromosome Aneuploidy
Interventions: no intervention; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 0 Days to 100 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2037
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetic Foot Ulcer
Interventions: Chlorhexidine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes, Hypoglycemia Unawareness
Interventions: somatostatin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Overweight or Obesity, Diabetes Mellitus, Type 2, Physical Inactivity
Interventions: Physical Activity, Delayed intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 75 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Type 2
Interventions: BMS-770767, Placebo, Metformin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Lomita, California • Las Vegas, Nevada

Conditions: Prediabetes
Interventions: INVENT Secure Messaging Intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Up to 75 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Chapel Hill, North Carolina • Dallas, Texas • Irving, Texas

Conditions: Diabetes
Interventions: Diabetes Survival Skills Training; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older · Male only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 21
States / cities: Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more

Conditions: Menopause, Prediabetes, Obesity
Interventions: Placebo, conjugated estrogens/bazedoxifene (CE/BZA); Other · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 60 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hypertension, Diabetes Mellitus, Maternal Health
Interventions: digital health delivered multicomponent intervention; Behavioral
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 22,340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Platinum Resistant Ovarian Cancer
Interventions: losartan, Paclitaxel; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gestational Diabetes, Pregnancy Related
Interventions: Insulin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Rochester, New York • Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes Mellitus
Interventions: Boost shake; Dietary Supplement
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Periodontitis, Diabetes Mellitus Type 2
Interventions: local antibiotic application of topical minocycline, Scaling and Root Planing; Drug · Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ovarian Cancer
Interventions: Investigator's choice of Chemotherapy, Azenosertib; Drug
Lead sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 16
States / cities: Phoenix, Arizona • Antioch, California • Beverly Hills, California + 12 more

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: intravenous docetaxel with intraperitoneal oxaliplatin, intravenous oxaliplatin with intraperitoneal docetaxel; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Improving Diabetes Care Through Effective Personalized Patient Portal Interactions

Michigan Genetic Hereditary Testing (MiGHT)

Pilot Study to Assess the Proteome in Human Atrial Tissue

Generating Advancements Through Longitudinal Analysis in X and Y Variations (GALAXY)

Preventing Diabetic Foot Ulcers Through Cleaner Feet

Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness

PA Moves Trial - Patient Participants

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT)

DIALYSIS-TIR Study

Diabetes Survival Skills + (DSS+) Training Intervention for Incarcerated Persons Transitioning to the Community (TTC)

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans

Examining Digital Health Care Delivery Models Through Medicaid Collaborative

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

Detection of C-peptide in Youth With Longstanding Type 1 Diabetes Mellitus

Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Glycated Albumin Monitoring

Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer